Health Condition 1: G409- Epilepsy, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Yakshdeep Dave PhD Research Scholar
Eligibility
Inclusion criteria
Inclusion criteria: Male or female patients more than 18 to less than 75 years suffering from all types of epilepsy and treated with oral Lacosamide either as monotherapy or as an adjuvant therapy. Patients followed up for 12 months. Patients should have 2 reported follow up (between 1 to 12 months) following dose titration.
Exclusion criteria
Exclusion criteria: Patient aged less than 18 years and more than 75 years to be excluded. Cases with incomplete medical records Patients with hypersensitivity to lacosamide Uncontrolled metabolic disorders like, hypertension, T2DM, dyslipidemia, thyroids disorders etc. Patients with compromised liver/renal/cardiac functions Epilepsy patients treated with IV lacosamide Hospitalized Epilepsy patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in MoCA cognitive scale from baseline to 6 months and 12 months % reduction in seizure frequency/month from baseline to at 6 months and 12 months Patients achieving continuous seizure freedom at 6 months and 12 monthsTimepoint: At baseline, 6 months & 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of AE/SAE/discontinuation from LCM therapy Sociodemographic analysis of patients Evaluation of drug utilization pattern in epilepsy Patients achieving seizure freedom at 6 months & 12 monthsTimepoint: At baseline, 6 months & 12 months | — |
Countries
India
Contacts
Public ContactYakshdeep Dave
NIRMA UNIVERSITY
Outcome results
None listed